Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain : A Literature Review
Daudén, E. (Hospital Universitario de la Princesa (Madrid))
Ortiz-Salvador, J.M. (Hospital General Universitario de Valencia)
Notario, Jaime (Hospital Universitari de Bellvitge)
Puig Sanz, Lluís (Institut de Recerca Sant Pau)
Santos-Juanes, Jorge (Hospital Universitario Central de Asturias)
Herrera-Acosta, E. (Hospital Clínico Virgen de la Victoria)
Gómez-Labrador, L. (Novartis Farmacéutica S.A.)
Ruíz Villaverde, Ricardo (Instituto Biosanitario de Granada)
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Background/Objectives: Secukinumab was shown to be effective in treating moderate-to-severe plaque psoriasis in adults and pediatric patients ≥6 years. Methods: A literature review was conducted to identify studies published in the preceding 5 years assessing the effectiveness and/or survival (safety in the second instance) associated with secukinumab treatment for moderate-to-severe plaque psoriasis with/without psoriatic arthritis (PsA) in real-world clinical practice in Spain. Results: 11 references were included, corresponding to seven studies (six retrospective and one prospective) (n = 1050). Baseline characteristics were mean age 46. 5-53. 0 years; 28. 7-55. 0% women; 30. 0-53. 1% patients with PsA; 27. 9-47. 4% naïve to biologic treatments; mean Psoriasis Area and Severity Index (PASI) score 12. 5 (standard deviation [SD]: 6. 9)-18. 1 (SD: 10. 3). PASI 90 response rates were 54-65% at Week 24 and 46-63% at Week 52; 43-47% of patients showed PASI ≤ 1 at Week 12 and 47-56% at Week 52. Treatment persistence at Week 52 was 72-89%, being 74. 5% in the larger cohort series (n = 384) at 2 years. Adverse-event-related treatment discontinuation was rare. Conclusions: Secukinumab demonstrated long-term safety and efficacy in treating adult patients with moderate-to-severe plaque psoriasis in actual clinical practice, with survival rates of up to two years and consistent efficacy in Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Spain ; Psoriasis; real-world evidence ; Secukinumab
Publicat a:	Journal of clinical medicine, Vol. 14 Núm. 2 (january 2025) , p. 478, ISSN 2077-0383

DOI: 10.3390/jcm14020478
PMID: 39860484

12 p, 797.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats